DBV Technologies posts results of Phase 3 DBV712 study in peanut-allergic children
The study, completed with 304 participants, posted results on ClinicalTrials.gov on October 28, 2026. It was an open-label extension of the EPITOPE study evaluating long-term clinical benefit and safety of DBV712 in peanut-allergic children.
Primary source
ClinicalTrials.gov results record, October 28, 2026
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Read the source: Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation